Stay updated on Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoChange DetectedAdded update dates 2026-05-20, 2026-05-05, and 2026-05. Removed 2025-11-18, 2025-11-05, and 2025-11, reflecting changes to the page's revision history.SummaryDifference0.2%

- Check12 days agoChange DetectedAdded the page revision tag v3.5.4 to replace the previous v3.5.3, indicating the page was updated. This update appears to reflect a revision history change rather than content changes to the study details.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page’s displayed revision number has been updated from v3.5.0 to v3.5.3.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check83 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. There are no changes to the study content or user-facing information on the page.SummaryDifference0.0%

- Check105 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. This appears to be a minor software version update with no visible changes to the study information.SummaryDifference0.0%

Stay in the know with updates to Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talimogene Laherparepvec & Pembrolizumab in Melanoma Clinical Trial page.